UCB SA (OTCMKTS:UCBJY) Sees Significant Drop in Short Interest

UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 7,614 shares, a decrease of 63.8% from the October 15th total of 21,017 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 76,592 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

A number of equities analysts have recently commented on UCBJY shares. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, UCB currently has an average rating of “Buy”.

View Our Latest Research Report on UCBJY

UCB Trading Up 0.8%

Shares of OTCMKTS:UCBJY traded up $1.34 during midday trading on Friday, hitting $163.75. The company’s stock had a trading volume of 14,056 shares, compared to its average volume of 31,350. The stock’s 50 day simple moving average is $131.08 and its 200 day simple moving average is $140.66. UCB has a fifty-two week low of $110.55 and a fifty-two week high of $168.76.

About UCB

(Get Free Report)

UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.

See Also

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.